We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avingtrans Plc | LSE:AVG | London | Ordinary Share | GB0009188797 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
10.00 | 2.56% | 400.00 | 390.00 | 410.00 | 400.00 | 390.00 | 390.00 | 12,940 | 14:00:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Engineering Services | 116.95M | 5.19M | 0.1579 | 25.33 | 131.59M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/2/2024 22:45 | MRI without the need for helium would be hugely cost saving in the longer term. It's expensive to buy and store, and increasingly difficult to source. | tratante | |
28/2/2024 11:41 | Yes they were that good. The acquisitions cost them 13 million last year. Someone on Stockopedia said about Adaptix not being able to attract any other offers. Firstly Avg already had 10 percent of the business and secondly they invited them to find a better offer. This is what Avg are renowned for, taking over businesses that have potential but cash strapped, building the business up to profitability and selling it on. It doesn’t happen over night. The nuclear waste business is booming and still no competitors in a sector they can barely service on their own . The cancelled rail works has not affected them at all and think there will be additional work there. The applications and potential for Adaptix and Magnetica are not even fully realised yet, way beyond just medical. I agree health authorities are under pressure, but actually these products could well help reduce workloads as time saving potential is huge. On the veterinary side , there will be no such problem as pet spend ever increases. Their markets are mostly in areas that are not cyclical, they are essential. Of course their is capital required in these projects. That is the mainstay of their business. Buy companies cheap, invest and sell | earwacks | |
28/2/2024 11:24 | usual problem with new medtech is slow adoption by bureaucratic health systems constrained by budgets even should the technology represent an obvious advance. | 1c3479z | |
28/2/2024 09:50 | Really? Were they that good? For all the big rise in revenue, operating profit margins are low and cash flow poor. Medical division set to be a drain on cash for the next two years plus. Good long-term management track record on disposals, but jury is out on Adaptix and Magnetica. | redwing1 | |
28/2/2024 09:31 | Absolutely agree, and even better to come as the new medical technology comes on stream and adds to the bottom line. | tratante | |
28/2/2024 09:21 | Fantastic update as expected, actually slightly better in many areas. Obviously already invested here, but now I know where to stick any spare cash as it becomes available. Really impressive uk business | earwacks | |
28/2/2024 08:21 | when is the dividend to be paid - couldn't see it | alter ego | |
28/2/2024 08:21 | In this fascinating interview, CEO Steve McQuillan & CFO Stephen King of Avingtrans take me through today’s in line H1’24 results and positive outlook. | brummy_git | |
28/2/2024 07:22 | Another encouraging & 'in line' set of numbers and guidance from niche engineer Avingtrans today. All the details & commentary here | brummy_git | |
12/2/2024 13:12 | allstar_07 this was raised on stocko last week. A poster called Jonno replied as follows. "The reason for the sharp decline in EPS at Avingtrans (LON:AVG) relates to the investment required to scale its medical division (Adaptix and Magnetica) . According to house broker Cavendish the nascent medical division has net assets of £9.5mn but will record an operating loss of £6.9mn for the year to 31 May 2024 and a further loss £6.4mn the following year. These losses will be covered by forecast annual operating profit £12mn and £13.3mn, respectively, from the group’s energy division. As a result of this investment Avingtrans (LON:AVG) pre-tax profit is estimated to decline from £9mn to £2.3mn in the new financial year. However assuming Avingtrans (LON:AVG) is successful in commercialising its portable X-ray scanner (adaptix) and portable helium free MRI device (Magnetica) the capital return will be substantial. The management at Avingtrans (LON:AVG) have proven themselves to be adept and astute and I am happy to remain invested." | alter ego | |
12/2/2024 12:02 | Hi, do you know why the drop from 24p to 2p? Because of the increased losses or other reasons? Seems extreme. | allstar_07 | |
11/2/2024 20:43 | I have been catching up on these given the recent price drop to see if I should buy more but will keep my hands in my pockets. That said, uncomfortable being out of these as say the sale of Booth would give them a comfortable rerating although we will need to show continued patience ref monetizing the HT Luton site. I agree that a good deal of potential in Medical but even with the current shareprice drop,basic eps of last year's continuing and discontining earnings is approx 23x. Of course with both Cavendish and Singer forecasting an adjusted eps of 2.8p for this current FY the PE even at current prices becomes extreme. I note Cavendish have a TP at 495p and for Singer it is 510p. I am comfortable we will get to these prices in 2025. I also note the issue of high receivables, the 1.2 PC approx dividend yield and no share buybacks in the offing and their lack of interest in shareholders like me. . | cerrito | |
09/2/2024 20:57 | Those forecasts are ballpark as the company now owns Adaptix and a larger slice of Magnetica which will both be loss making this year as AVG invests towards commercialisation of their 3d x-ray and MRI products. I accept the UK market is probably not mature enough to look beyond the PE ratio but it really isn't the best way to value companies like AVG. | cockerhoop | |
09/2/2024 17:07 | Does anyone have reliable forecasts for this year and next? Stocko has c2p down from 24p a few months ago! | allstar_07 | |
20/1/2024 09:10 | I changed the https to hTTps | alter ego | |
20/1/2024 09:09 | this is what I see | alter ego | |
20/1/2024 08:39 | @ brummy_git.... All your posts end with "all the details here". Where is "here" exactly? On my device at least the word "here" isn't a link ?! | moneymarty | |
18/1/2024 18:52 | I agree but I found the reasons for undertaking the amalgamation a little bit perplexing. | dgwinterbottom | |
18/1/2024 08:28 | yes, use of word "mature" seems to indicate that. | alter ego | |
18/1/2024 07:27 | Looks like first stage of a disposal being lined up. | 18bt | |
18/1/2024 07:21 | More positive news from specialist engineering & medical devices firm Avingtrans today. All the details here. | brummy_git | |
04/12/2023 08:32 | Magnetica distributor signed up for North America. Product well received at exhibition. Fantastic news. The this part of the business currently valued at nill point by this pathetic market. | earwacks | |
26/11/2023 14:42 | Options @£3.9 not exercisable for 3 years from grant date. This looks a fair deal, not like some companies that just take the mick and want shares for nothing. This sets a good precedent that Other Aim companies would do well to take notice of | earwacks | |
16/11/2023 14:57 | Default AGM trading update | primarch1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions